Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
March 02 2023 - 8:00AM
Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence (AI) and machine learning (ML) platform to transform
the cost, pace, and timeline of oncology drug discovery and
development, today announced that it has expanded its clinical
development team with the addition of Dr. Reggie Ewesuedo M.D.,
M.Sc., MBA, as Vice President of Clinical Development, and several
additional team members. The expansion of the clinical development
team will continue to advance the Harmonic™ trial, a Phase 2 trial
for never smokers with NSCLC, as well as the upcoming
first-in-human Phase 1 clinical trials for Lantern’s drug
candidates LP-184 and LP-284, which are both anticipated to launch
in mid-2023.
“We are looking forward to the many contributions that Dr.
Ewesuedo and our expanded clinical development team will bring to
Lantern and our clinical programs,” said Panna Sharma, Lantern’s
President and CEO. “They are joining Lantern at a pivotal period in
our company’s growth as we advance our drug candidates into and
through clinical trials. I am confident in the decades of proven
experience of our new team members and their ability to progress
Lantern’s drug candidates to improve the lives of cancer patients,”
continued Sharma.
Dr. Ewesuedo has over 20 years of experience in preclinical,
early, and late phase drug development including roles in clinical
development leadership at AstraZeneca, Genzyme/Sanofi, Pfizer,
Tesaro/GlaxoSmithKline, and Kymera. His leadership and experience
have led to the development of several drugs including the
successful filings for Trazimera™ (trastuzumab), Nyvepria™
(pegfilgrastim), and Zirabev™ (bevacizumab), while he was at
Pfizer. In addition to his industry experience, he also served as a
clinical research faculty member at The Ohio State University from
2000-2005. He holds an M.D. from the University of Ibadan, College
of Medicine, Ibadan, Nigeria, a M.Sc. in Pharmacology from Ahmadu
Bello University, Zaria, Nigeria, and an MBA from St. Mary’s
University, Greehey Business School, San Antonio, TX. Dr. Ewesuedo
completed his subspecialties training in Hematology and Pediatric
Oncology, and Clinical Pharmacology and Pharmacogenomics, at the
University of Chicago.
Lantern has also recently appointed Ernest Kitt as Head of
Clinical Operations. Mr. Kitt has over 20 years of experience in
oncology drug development and clinical operations with proven
success in bringing drugs to market. He has held clinical oncology
leadership positions at companies including Amgen/Onyx, Aptose, and
Biosplice. Other additions to the clinical development team include
Annum Zhara as a Senior Clinical Trial Project Manager and Brianna
MacCrory as a Clinical Trial Navigator.
About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® AI and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. By targeting
drugs to patients whose genomic profile identifies them as having
the highest probability of benefiting from the drug, Lantern's
approach represents the potential to deliver best-in-class
outcomes.
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® AI platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230302005267/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Lantern’s
Monthly Newsletter – The SPARK: Sign-up here Twitter:
@lanternpharma
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024